The Valley Desk

NCT02890381 · Interventional trial

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age

Overall registry status Terminated

Phase 1

Conditions Respiratory Syncytial Virus Infections

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov